NDC STATEMENT ON COURT RULING. (PHOTO). #PRESS RELEASE.

Image
 NDC STATEMENT ON COURT RULING Our attention has been drawn to a ruling by the Federal High Court sitting in Lokoja this morning, wherein His Lordship, Honourable Justice Isah Dashen, gave a ruling on an application filed by an unregistered association known as Peace Movement Party. The public knows that by December 2025, the Nigeria Democratic Congress  as an association complained of INEC’s refusal to register us as a political party, whereupon we proceeded to the Federal High Court. The Federal High Court upheld our constitutional right to freedom of association under the Constitution and compelled INEC to register us, which INEC did. Since then, we have started political activities, embarked on the registration of members, held congresses from ward to national levels, held conventions, and concluded primaries to all offices following INEC’s timetable. We have been fully participating in all INEC activities without let or hindrance. NDC also fielded candidates, and fully pa...

NEW DRUG MAY BOOST SURVIVAL FOR CHILDREN WITH RARE BONE CANCER.(PHOTO).


 New drug may boost survival for children with rare bone cancer

Children with a rare bone cancer may have better survival chances when treated with a drug that cuts off the blood supply to tumors, researchers report.

The medication, pazopanib (Votrient), appeared to extend the lives of a small group of children with Ewing sarcoma, a cancer that forms tumors in the bones, according to findings published in Frontiers in Oncology.

“While we wait for new treatment options, it is possible to implement this existing drug to improve outcomes in very high-risk patients,” said Anna Raciborska, head of oncology at Poland’s Warsaw Mother and Child Institute. “It opens the door to targeted therapies earlier in the disease course, potentially improving survival and quality of life.”

Typically, fewer than 25% of children with advanced Ewing sarcoma survive five years after diagnosis. Researchers explored pazopanib, originally developed for kidney cancer, as a potential way to slow the disease.

“Pazopanib is a pill that blocks the tumor’s ability to grow new blood vessels, which tumors need to survive and spread,” Raciborska said. “By cutting off this ‘blood supply,’ the drug presumably makes tumors weaker and more sensitive to chemotherapy and radiation, which may slow the disease and enhance the effectiveness of existing treatments.”

From 2016 to 2024, 11 children aged 5 to 18 received pazopanib alongside standard therapies, including chemotherapy, surgery, radiation, or stem cell transplants. Results showed that roughly 86% of the children survived two years after diagnosis, while about 68% experienced no progression in their cancer.

Currently, 10 of the children are still alive, with six continuing to take pazopanib. One patient’s cancer progressed, and two experienced a relapse. The drug also caused minimal side effects.

Researchers stressed that larger studies are needed to confirm the findings, though the rarity of advanced Ewing sarcoma makes enrolling patients in clinical trials challenging.

“While the results are encouraging, larger controlled trials are needed before changing standard practice,” Raciborska said. “Our study could serve as a basis for creating prospective, multicenter trials to confirm these promising results, but it will require significant work and resources.”


Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).